Jiang ZQ, Varadhachary G, Wang X, Kopetz S , Lee JE , Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ
The greater magnitudes of bodyweight reduction seen in this trial, as well as the improvements in cardiovascular risk factors and glucose control, can have beneficial effects on health goals in clinical practice. In the STEP UP T2D trial, a higher semaglutide dose resulted in an average bodyweight reduction of 13.2%, compared to 10.4% for the standard dose and 3.9% for the placebo
Tirzepatide (Mounjaro for T2DM, Zepbound for obesity): a dual GLP-1/GIP agonist
PCOS Treatment for Hormone Balance, Wellness, Hair and Nail Health
Regardless of which option you choose, your treatment plan is designed to support long-term progress and minimize risk
With so many online weight loss programs flooding the market, finding one thats medically sound feels overwhelming